New Protein Signature Could Tackle Prostate Cancer Resistance
A new study identifies a potential biological pathway that may help restore drug sensitivity in some prostate cancer cases.
Updated on Oct. 15, 2026 in Cancer
Researchers have identified a new protein signature involving CDK5R1 that may contribute to prostate cancer progression and drug resistance. This preclinical study, published on October 15, 2026, also suggests that the bioactive compound oridonin could help restore sensitivity to the drug enzalutamide in resistant cancer cells.
Why it matters
Advanced prostate cancer often stops responding to standard treatments like enzalutamide, creating an urgent need for new therapeutic targets. By mapping how specific proteins and immune cells interact, this research offers a potential pathway to overcome drug resistance in the future.
This preclinical analysis utilized network pharmacology, spatial transcriptomics, and cellular experiments to identify a CDK5R1-centered prognostic signature. It remains unknown how other constituents of the Qiling Formula contribute to these findings.
The players
Qiling Formula
A traditional formulation designed to target Qi deficiency and blood stasis in oncology research.
The details
The study found that CDK5R1-positive tumor cells often co-localize with SPP1-positive macrophages, which are known to suppress the immune system. The researchers determined that the compound oridonin, a component of the Qiling Formula, works by disrupting the CDK5R1-androgen receptor (AR) axis. By targeting this specific interaction, oridonin may help re-sensitize prostate cancer cells to enzalutamide treatment.
Timeline
October 15, 2026: Findings were published in a new analysis.
Health Landscape
Treatment resistance is a primary hurdle in the management of advanced prostate cancer. This research aligns with ongoing efforts to map the tumor microenvironment to identify novel targets beyond the standard androgen receptor pathways.
These findings are strictly preclinical and do not currently change treatment options for patients. Patients should continue their prescribed therapy and discuss any concerns about drug resistance or new research developments with their oncologist.
The takeaway
This study highlights how specific proteins and immune cells interact to foster drug resistance in prostate cancer. If you are undergoing treatment for prostate cancer, maintain open communication with your care team regarding your progress and any changes in your treatment response.
Further reading
For more information on how researchers are studying new treatments, visit our Cancer section.
Source note: This article includes information reported by Nature.
